Clinical trials data collection: When less is more

Journal of Clinical Oncology

Volumn 28, Issue 34, 2010, Pages 5019-5021

  Sargent, Daniel J ^a   George, Stephen L ^b  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG INFORMATION; DRUG RESEARCH; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION PROCESSING; NATIONAL HEALTH ORGANIZATION; ONCOLOGY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 79951901336     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.7024     Document Type: Editorial

References (19)

1. Institute of Medicine: A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC, The National Academies Press, 2010
2. Varmus H: Director's Page: NCI Town Hall Meeting - July 12, 2010.http://www.cancer.gov/director/page42
3. Dilts DM, Sandler AB, Cheng SK, et al: Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol 27:1761-1766, 2009
4. Operational Efficiency Working Group of the Clinical Trials and Translational Research Advisory Committee: Restructuring the National Cancer Clinical Trials Enterprise. 2005 http://restructuringtrials.cancer.gov/files/ ctwg-report.pdf
5. Operational Efficiency Working Group of the Clinical Trials and Translational Research Advisory Committee: Compressing the Timeline for Cancer Clinical Trial Activation. 2010 http://ccct.cancer.gov/files/OEWG-Report.pdf
6. Peto R, Collins R, Gray R: Large-scale randomized evidence: Large, simple trials and overviews of trials. J Clin Epidemiol 48::23-40, 1995
7. QUASAR Collaborative Group, Gray R, Barnwell J, McConkey C, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007 (Pubitemid 350236339)
8. Garber AM, Tunis SR: Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 360:1925-1927, 2009
9. Kaiser LD, Melemed AS, Preston AJ, et al: Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol 28:5046-5053, 2010
10. Roche K, Paul N, Smuck B, et al: Factors affecting workload of cancer clinical trials: Results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 20:545-556, 2002 (Pubitemid 34081107)
11. Mahoney MR, Sargent DJ, O'Connell MJ, et al: Dealing with a deluge of data: An assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol 23:9275-9281, 2005
12. Hillman SL, Mandrekar SJ, Bot B, et al: Evaluation of the value of attribution in the interpretation of adverse event data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation. 28:3002-3007, 2010
13. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001 (Pubitemid 32880058)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Hillman SL, An MW, O'Connell MJ, et al: Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: A north central cancer treatment group investigation. J Clin Oncol 27::3205-3210, 2009
16. Bogaerts J, Ford R, Sargent D, et al: Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 45:248-260, 2009
17. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
18. Institute of Medicine: Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, DC, The National Academies Press, 2010
19. George SL: Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 14:1364-1370, 1996